211 related articles for article (PubMed ID: 16027408)
1. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine.
Dmochowski R; Chen A; Sathyan G; MacDiarmid S; Gidwani S; Gupta S
J Clin Pharmacol; 2005 Aug; 45(8):961-8. PubMed ID: 16027408
[TBL] [Abstract][Full Text] [Related]
2. Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin.
Sathyan G; Dmochowski RR; Appell RA; Guo C; Gupta SK
Clin Pharmacokinet; 2004; 43(14):1059-68. PubMed ID: 15530134
[TBL] [Abstract][Full Text] [Related]
3. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin.
Perfetto EM; Subedi P; Jumadilova Z
Am J Manag Care; 2005 Jul; 11(4 Suppl):S150-7. PubMed ID: 16161388
[TBL] [Abstract][Full Text] [Related]
4. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.
Chu FM; Dmochowski RR; Lama DJ; Anderson RU; Sand PK
Am J Obstet Gynecol; 2005 Jun; 192(6):1849-54; discussion 1854-5. PubMed ID: 15970828
[TBL] [Abstract][Full Text] [Related]
5. High performance liquid chromatography-electrospray ionization mass spectrometric determination of tolterodine tartrate in human plasma.
Zhang B; Zhang Z; Tian Y; Xu F
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Sep; 824(1-2):92-8. PubMed ID: 16043426
[TBL] [Abstract][Full Text] [Related]
6. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder.
Varadharajan S; Jumadilova Z; Girase P; Ollendorf DA
Am J Manag Care; 2005 Jul; 11(4 Suppl):S140-9. PubMed ID: 16161387
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
Oki T; Kageyama A; Takagi Y; Uchida S; Yamada S
J Urol; 2007 Feb; 177(2):766-70. PubMed ID: 17222678
[TBL] [Abstract][Full Text] [Related]
8. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine.
Olsson B; Szamosi J
Clin Pharmacokinet; 2001; 40(3):227-35. PubMed ID: 11327200
[TBL] [Abstract][Full Text] [Related]
9. A formulation approach for development of HPMC-based sustained release tablets for tolterodine tartrate with a low release variation.
Cao QR; Choi JS; Liu Y; Xu WJ; Yang M; Lee BJ; Cui JH
Drug Dev Ind Pharm; 2013 Nov; 39(11):1720-30. PubMed ID: 23062115
[TBL] [Abstract][Full Text] [Related]
10. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
Bolge SC; McDonnell DD; Chen A; Wan GJ
Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
[TBL] [Abstract][Full Text] [Related]
11. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
[TBL] [Abstract][Full Text] [Related]
12. Persistence with overactive bladder pharmacotherapy in a Medicaid population.
Shaya FT; Blume S; Gu A; Zyczynski T; Jumadilova Z
Am J Manag Care; 2005 Jul; 11(4 Suppl):S121-9. PubMed ID: 16161385
[TBL] [Abstract][Full Text] [Related]
13. Advances in medical management of overactive bladder.
Richelson E; Elliott DS
Mayo Clin Proc; 2003 Jun; 78(6):681-3. PubMed ID: 12934775
[No Abstract] [Full Text] [Related]
14. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials.
Armstrong RB; Dmochowski RR; Sand PK; Macdiarmid S
Int Urol Nephrol; 2007; 39(4):1069-77. PubMed ID: 17333521
[TBL] [Abstract][Full Text] [Related]
15. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
[TBL] [Abstract][Full Text] [Related]
16. Tolterodine extended-release for overactive bladder.
Chung DE; Te AE
Expert Opin Pharmacother; 2009 Sep; 10(13):2181-94. PubMed ID: 19663610
[TBL] [Abstract][Full Text] [Related]
17. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin.
Reiz JL; Salem P; Darke AC
J Clin Pharmacol; 2007 Mar; 47(3):351-7. PubMed ID: 17322147
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
Gupta SK; Sathyan G
J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.
Appell RA; Chancellor MB; Zobrist RH; Thomas H; Sanders SW
Mayo Clin Proc; 2003 Jun; 78(6):696-702. PubMed ID: 12934778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
